SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2182Is Roche making mistake(s)? Their bigger one was favoring PD-L1 instead PD1 (escMiljenko Zuanic-8/8/2017
2181Did Sanofi made same mistake with Fasinumab, as it did with Eylea???? Well, 2Q bMiljenko Zuanic-8/4/2017
2180I agree, they need second drug, not just 'scientifically sound" candidaMiljenko Zuanic-8/3/2017
2179Motivated companies know where the next growth will come from. I believe I haveBiotech Jim-8/3/2017
2178<Report results from Phase 3 asthma program in adults and adolescents> ThMiljenko Zuanic-8/3/2017
2177Next time/Q they should report 60-80 cents miss, so stock can rally few percent!Miljenko Zuanic-8/3/2017
2176<I presume Miljenko is happy about sunset of SNY antibody collaboration> Miljenko Zuanic18/3/2017
2175I presume Miljenko is happy about sunset of SNY antibody collaboration: investorDewDiligence_on_SI-8/3/2017
2174<It appears that Eylea will do well in 2Q...> $919 M is even bit better tMiljenko Zuanic-8/3/2017
2173Looking forward... Select Upcoming 2017 Milestones Programs Milestones Biotech Jim-8/3/2017
2172Time will tell, their (and the rest of industries) ADC development has been a biFelix B-8/1/2017
2171This plus Lilly's failure tighten up the market, curious if they can chip awFelix B-8/1/2017
2170Sure they can, with anti-CD38 antibody (sanofi) for hematology and ant-LAG-3 (REMiljenko Zuanic-7/31/2017
2169Stil early to tell but looks like PD1 rather than PD1-L is the better target. Felix B-7/31/2017
2168AD market is not RA/psoriasis or cancer! Not even close. I mentioned early that Miljenko Zuanic-7/31/2017
2167Have you seen the commercial-uptake chart for Eliquis? In early quarters, it looDewDiligence_on_SI-7/31/2017
2166Difference between IL-6 and IL-6R (in RA): endpts.comMiljenko Zuanic-7/31/2017
2165<Small consolation, but €26M recorded sales is about $30.6M (not $28.6M). RegMiljenko Zuanic-7/31/2017
2164Small consolation, but €26M recorded sales is about $30.6M (not $28.6M). RegardsDewDiligence_on_SI-7/31/2017
2163<One needs a telescope to see the $5B sales peak.> At this point even T. Miljenko Zuanic-7/31/2017
2162Law360, New York (July 27, 2017, 7:51 PM EDT) -- The Federal Circuit said ThursdThe Ox-7/31/2017
2161SNY Q2 results included $28.6M in Dupixent (dupilumab) sales, below expectationBiotech Jim-7/31/2017
2160<In addition to tonight Sanofi 2Q report, I think that next week is importantMiljenko Zuanic-7/31/2017
2159One small clarification from Bayer 2Q Eylea sale....smaller than expected growthMiljenko Zuanic-7/30/2017
2158It appears that Eylea will do well in 2Q, Roche Lucentis US sale for 2Q decline Miljenko Zuanic-7/27/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News